SGYP Share Price

Open 6.24 Change Price %
High 6.29 1 Day -0.32 -5.78
Low 5.03 1 Week -0.08 -1.51
Close 5.22 1 Month -0.09 -1.69
Volume 20257050 1 Year -0.88 -14.43
52 Week High 6.29
52 Week Low 0.00
SGYP Important Levels
Resistance 2 6.39
Resistance 1 5.91
Pivot 5.51
Support 1 4.53
Support 2 4.05
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP)

SGYP Technical Analysis 2
As on 9th Dec 2016 SGYP Share Price closed @ 5.22 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.16 & Sell for SHORT-TERM with Stoploss of 5.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGYP Target for December
1st Target up-side 6.23
2nd Target up-side 6.91
3rd Target up-side 7.59
1st Target down-side 4.29
2nd Target down-side 3.61
3rd Target down-side 2.93
SGYP Other Details
Segment EQ
Market Capital 240850608.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.synergypharma.com
SGYP Address
SGYP
420 Lexington Avenue
Suite 2012
New York, NY 10170
United States
Phone: 212-297-0020
Fax: 212-297-0019
SGYP Latest News
Interactive Technical Analysis Chart Synergy Pharmaceuticals, Inc. ( SGYP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Synergy Pharmaceuticals, Inc.
SGYP Business Profile
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.